About Birken
Birken is a Healthcare company based in Niefern-oschelbronn (Germany) founded in 2000, and was acquired by Amryt Pharma in March 2016. German, clinical-stage biopharma developing botanical-origin extract for wound healing. Its chief executive, as recorded, is Joseph Wiley. The company was acqui-hired. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders.
Company details
Birken was founded in 2000 as a German clinical-stage biopharmaceutical company. Focus was placed on developing botanical extracts, particularly Episalvan from birch bark, for epidermolysis bullosa treatment. Orphan Drug designations were obtained in the US and Europe. Anti-microbial and anti-inflammatory properties are shown by Episalvan, supporting skin repair processes. Operations centered in Germany until acquisition by Amryt Pharma in 2016.
- Headquarters Niefern-oschelbronn, Germany
- Stage Acquired
- SectorsHealthcare
- Website birken.eu
- Acquired by Amryt Pharma (Mar 2016)
- Investors
- Acquired byAmryt Pharma
(Mar 2016)
Investors in Birken
Birken has secured backing from 1 investor. Prominent investors backing the company include Amryt Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for rare dermatological and orphan diseases are developed. | 2015 | amrytpharma.com | Dublin, Ireland |
Investor details for Birken
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Birken
1 people are tracked at Birken (1 in leadership).
| Name | Role | Group |
|---|---|---|
Joseph Wiley | CEO | Leadership |
Complete people profiles for Birken
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Birken
2 dated milestones of Birken across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Birken is founded.
- Exit Acquired by Amryt Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Birken
Birken was founded in 2000.
Birken is headquartered in Niefern-oschelbronn, Germany. It is registered at Niefern-oschelbronn, Baden-wurttemberg, Germany.
Joseph Wiley is the CEO of Birken, as recorded in our data.
Birken was founded in 2000 as a German clinical-stage biopharmaceutical company. Focus was placed on developing botanical extracts, particularly Episalvan from birch bark, for epidermolysis bullosa treatment. Orphan Drug designations were obtained in the US and Europe. Anti-microbial and anti-inflammatory properties are shown by Episalvan, supporting skin repair processes. Operations centered in Germany until acquisition by Amryt Pharma in 2016.
Birken has 1 investor. Key investors include Amryt Pharma.
Yes. Birken was acquired by Amryt Pharma in March 2016.